Cure My Disease

Don't miss your cure!

 Log in / Sign up

Why COVID-19 lungs fail: tiny blood vessel damage may be key

NCT ID NCT05074758

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study investigates why COVID-19 causes severe lung injury (ARDS) by looking at tiny blood vessels in the lungs. Researchers will compare 39 patients with COVID-19 ARDS to those with ARDS from other causes. They measure 'alveolar dead space' — lung areas that get air but not blood flow — and check blood for signs of vessel damage and clotting problems. The goal is to understand if COVID-19 uniquely harms lung blood vessels, which could guide future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict outcomes and tailor treatments for COVID-19 patients with severe lung injury.
What could go wrong
This is a small observational study, not a treatment trial. It may not identify clear differences or lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

39 people

The number who actually took part.

Started

Dec 2021

Finished

Mar 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with moderate or severe ARDS linked or not with covid-19

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age\> 18 years old * Invasive mechanical ventilation in place for less than 48 hours * Severe or moderate ARDS (defined according to the Berlin classification) * Virological confirmation by PCR of SARS-CoV-2 infection (ARDS COVID-19) * Lack of virological confirmation by PCR of SARS-CoV-2 infection (ARDS not linked to COVID-19) * Patient information Exclusion Criteria: * Massive pulmonary embolism * Chronic respiratory failure under long-term oxygen therapy * Dying patient

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS, human are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS, human COVID-19 acute respiratory distress syndrome

Contacts and locations

Locations

  • Hôpital européen Georges Pompidou

    Paris, Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.